achieve the enormous potential of this business. The
time is now right for Jim to turn his full attention and energies back to
the core challenges facing the Company as a whole, especially those
relating to strategy, the development of our human capital, organizational
efficiency and effectiveness, and simplifying and streamlining operations.
We are committed to delivering innovation, profitable growth, increased
shareholder value, and a stronger Company for the future. The Board and I
firmly and unanimously believe Jim is the best person to continue
delivering on those commitments."
"Paul LaViolette has served this Company with passion and enthusiasm
for almost 15 years, and as a friend and colleague I want to thank him for
all he has done," added Nicholas.
"The Board of Directors continues to be very satisfied with Jim's
effective and skillful leadership of Boston Scientific," said Warren B.
Rudman, Director and Chairman of the Executive Compensation and Human
Resources Committee of the Board of Directors. "All of us on the Board
believe Jim remaining CEO is in the best interest of the Company, its
employees, customers, patients and shareholders. We look forward to Boston
Scientific realizing its full potential under Jim's leadership, and to its
ongoing role as a global leader in the medical device industry."
"In the nine years I have had the honor of leading Boston Scientific,
we have accomplished a great deal and made remarkable progress, but there
is more to do," said Tobin. "Across the organization, our accomplishments
are the result of thousands of people around the world who every day
advance our mission of helping clinicians improve patients' lives through
medical technology. Nowhere is the promise of medical technology greater
than in CRM. For the past two years, I have had the pleasure of working
directly with our talented and dedicated CRM team to rebuild that
organization and make it world class again. During this time, the
Page: 1 2 3 4 5 Related biology technology :1
|SOURCE Boston Scientific Corporation|
Copyright©2008 PR Newswire.
All rights reserved
. NanoLogix Inc. to Present at The American Society for Microbiology (ASM) General Meeting in Boston; Announces Product Line and Provides Operations Update2
. Boston Scientific Completes Acquisition of CryoCor3
. Boston Scientific Announces Launch of Expanded Size Range of FilterWire EZ(TM) Embolic Protection System4
. Boston Scientific Announces FDA Approval of New Heart Failure Lead5
. Boston Scientifics SpyGlass(R) Direct Visualization System to Be Prominently Featured at Digestive Disease Week(R)6
. Boston Scientific Announces Program to Analyze Latitude(R) Patient Monitoring Data7
. Boston Scientific Announces European Approval and Market Launch of New Family of Advanced Pacemakers8
. WIPO Panel Rules Boston Scientific Liberte(R) and TAXUS(R) Liberte(R) Stents Do Not Infringe Medinol Patents9
. Fraunhofer and Boston University Hosted Prestigious SME Tour10
. Boston-Based BioDefense Corp. Announces New UK Partnership to Expand Markets for Biohazard Protection11
. Boston Scientific Announces Results for First Quarter Ended March 31, 2008